Using nanopore technology to identify DNA changes for early detection of colorectal cancer
Single-molecule nanopore-based identification of methylome signatures in cfDNA for early colorectal cancer detection
This study is looking at blood samples to find early signs of colorectal cancer by checking for special patterns in DNA, using a new method that could help catch the disease sooner and more accurately than current tests.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10866755 on NIH RePORTER |
What this research studies
This research focuses on analyzing cell-free DNA (cfDNA) to detect early signs of colorectal cancer through a novel nanopore-based sequencing method. By examining the methylation patterns in cfDNA, the study aims to improve the sensitivity and accuracy of cancer detection compared to traditional methods. Patients' blood samples will be analyzed to identify specific epigenetic markers associated with early-stage cancer, potentially leading to earlier diagnosis and treatment. The approach seeks to overcome limitations of existing sequencing techniques that can introduce biases and inaccuracies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for colorectal cancer, including those with a family history or genetic predispositions.
Not a fit: Patients who are not at risk for colorectal cancer or those with advanced cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of colorectal cancer, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using cfDNA for cancer detection, but this nanopore-based approach represents a novel method that has not been widely tested.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Ji, Hanlee P — Stanford University
- Study coordinator: Ji, Hanlee P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.